Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2022 Update
07:10am, Wednesday, 19'th Oct 2022 Seeking Alpha
ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. Click to see the firm's trades for Q3 2022.
Expert Ratings for Incyte
08:05pm, Tuesday, 18'th Oct 2022 Benzinga
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
0
4
0
0
Last 30D
0
0
1
Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm'
05:59pm, Monday, 17'th Oct 2022 Benzinga
SVB Leerink initiated coverage on CTI Biopharma Corp (NASDAQ: CTIC) with an Outperform rating and a $13 price target.
CTIC is a commercial-stage biopharmaceutical company launching Vonjo — a d
Is Incyte (INCY) a Solid Growth Stock? 3 Reasons to Think "Yes"
04:45pm, Monday, 17'th Oct 2022 Zacks Investment Research
Incyte (INCY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
INCY vs. GMAB: Which Stock Is the Better Value Option?
03:40pm, Monday, 17'th Oct 2022 Zacks Investment Research
INCY vs. GMAB: Which Stock Is the Better Value Option?
Is Incyte (INCY) a Solid Growth Stock? 3 Reasons to Think "Yes"
03:03pm, Monday, 17'th Oct 2022
Incyte (INCY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now
02:43pm, Monday, 17'th Oct 2022 Zacks Investment Research
Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.
INCY vs. GMAB: Which Stock Is the Better Value Option?
12:48pm, Monday, 17'th Oct 2022
INCY vs. GMAB: Which Stock Is the Better Value Option?
2 Cathie Wood Stocks That Are Beating the Market This Year
08:15pm, Friday, 07'th Oct 2022 The Motley Fool
One is doing much better than the other year to date, but they both have solid prospects ahead.
2 Cathie Wood Stocks That Are Beating the Market This Year
04:15pm, Friday, 07'th Oct 2022
One is doing much better than the other year to date, but they both have solid prospects ahead.
Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart
04:26pm, Thursday, 29'th Sep 2022
Biotech has pulled back sharply after a summer rebound, but the niche continues to outperform the S&P 500. One mid-sized biotech company is looking forward to better earnings ahead with a decent pipel
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
10:20am, Wednesday, 14'th Sep 2022 Zacks Investment Research
Smart Beta ETF report for RYH
20 value stocks whose growth potential is overlooked by investors
05:06pm, Tuesday, 13'th Sep 2022 MarketWatch
Value stocks have held up better than growth stocks this year, and that trend may continue, according to analysts.
Pfizer (PFE) Alopecia Drug Filings Get Accepted by FDA, EMA
04:22pm, Monday, 12'th Sep 2022 Zacks Investment Research
FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
10:20am, Monday, 12'th Sep 2022 Zacks Investment Research
Sector ETF report for RYH
